| 000 | 01823 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250518084715.0 | ||
| 264 | 0 | _c20210602 | |
| 008 | 202106s 0 0 eng d | ||
| 022 | _a1868-7083 | ||
| 024 | 7 |
_a10.1186/s13148-020-0821-z _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGalle, Eva | |
| 245 | 0 | 0 |
_aDNA methylation-driven EMT is a common mechanism of resistance to various therapeutic agents in cancer. _h[electronic resource] |
| 260 |
_bClinical epigenetics _c02 2020 |
||
| 300 |
_a27 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAzacitidine _xtherapeutic use |
| 650 | 0 | 4 |
_aCarcinoma, Hepatocellular _xdrug therapy |
| 650 | 0 | 4 |
_aCell Line, Tumor _xdrug effects |
| 650 | 0 | 4 |
_aCirculating Tumor DNA _xgenetics |
| 650 | 0 | 4 |
_aDNA Methylation _xgenetics |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xgenetics |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aEpigenesis, Genetic |
| 650 | 0 | 4 |
_aEpithelial-Mesenchymal Transition _xgenetics |
| 650 | 0 | 4 |
_aGene Expression Regulation, Neoplastic _xgenetics |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLiver Neoplasms _xpathology |
| 650 | 0 | 4 |
_aMicroRNAs _xgenetics |
| 650 | 0 | 4 |
_aProtein Kinase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aSorafenib _xtherapeutic use |
| 700 | 1 | _aThienpont, Bernard | |
| 700 | 1 | _aCappuyns, Sarah | |
| 700 | 1 | _aVenken, Tom | |
| 700 | 1 | _aBusschaert, Pieter | |
| 700 | 1 | _aVan Haele, Matthias | |
| 700 | 1 | _aVan Cutsem, Eric | |
| 700 | 1 | _aRoskams, Tania | |
| 700 | 1 | _avan Pelt, Jos | |
| 700 | 1 | _aVerslype, Chris | |
| 700 | 1 | _aDekervel, Jeroen | |
| 700 | 1 | _aLambrechts, Diether | |
| 773 | 0 |
_tClinical epigenetics _gvol. 12 _gno. 1 _gp. 27 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/s13148-020-0821-z _zAvailable from publisher's website |
| 999 |
_c30636192 _d30636192 |
||